DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Evista (Raloxifene Hydrochloride) - Summary

 
 



WARNING: INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE

  • Increased risk of deep vein thrombosis and pulmonary embolism have been reported with EVISTA [see Warnings and Precautions ] . Women with active or past history of venous thromboembolism should not take EVISTA [see Contraindications].
  • Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke [see Warnings and Precautions and Clinical Studies].
 

EVISTA SUMMARY

EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds.

Treatment and Prevention of Osteoporosis in Postmenopausal Women

EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see Clinical Studies (14.1, 14.2)].

Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis

EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see Clinical Studies ].

Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women at High Risk of Invasive Breast Cancer

EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see Clinical Studies].

The effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see Clinical Studies]. Twenty-seven percent of the participants received drug for 5 years. The long-term effects and the recommended length of treatment are not known.

High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer ≥1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. Healthcare professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-800-545-5979. Currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.

After an assessment of the risk of developing breast cancer, the decision regarding therapy with EVISTA should be based upon an individual assessment of the benefits and risks.

EVISTA does not eliminate the risk of breast cancer. Patients should have breast exams and mammograms before starting EVISTA and should continue regular breast exams and mammograms in keeping with good medical practice after beginning treatment with EVISTA.

Important Limitations of Use for Breast Cancer Risk Reduction

  • There are no data available regarding the effect of EVISTA on invasive breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of EVISTA.
  • EVISTA is not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence.
  • EVISTA is not indicated for the reduction in the risk of noninvasive breast cancer.

See all Evista indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Evista (Raloxifene)

Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. [2014]
raloxifene to risperidone versus risperidone with placebo... CONCLUSIONS: According to our findings, raloxifene as an adjunctive treatment to

What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead? [2014]
The author considers hypothetical comparisons between oral conjugated equine estrogens and transdermal estradiol and between oral medroxyprogesterone acetate and oral micronized progesterone for their effects on four primary outcomes of the Women's Health Initiative (WHI): cardiovascular disease risk, cerebrovascular disease risk, venous thromboembolism risk, and breast cancer risk.

National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities. [2013]
understanding of breast cancer risk assessment in minority communities... CONCLUSIONS: Recruitment strategies used in STAR for racial and ethnic minorities

Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. [2011.11]
CONCLUSIONS: Raloxifene as an adjuvant treatment in postmenopausal women with schizophrenia who exhibit prominent negative symptoms appears to be useful in improving negative, positive, and general psychopathological symptoms. If more extensive and longer-term studies confirm and expand upon these positive results, the use of raloxifene could be recommended in postmenopausal patients with schizophrenia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01041092. (c) Copyright 2011 Physicians Postgraduate Press, Inc.

Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome. [2011.09]
OBJECTIVE: To compare the ovulation rate between raloxifene and clomiphene citrate (CC) in patients with polycystic ovary syndrome (PCOS)...

more studies >>

Clinical Trials Related to Evista (Raloxifene)

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis [Completed]
To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.

Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women [Completed]
The efficacy of raloxifene versus placebo was compared over a six-month period, as an adjuvant treatment of the negative symptoms of schizophrenia in a group of 80 post-menopausal women. The aim of the study is to analyze whether raloxifene has an effect on the positive and negative symptoms of schizophrenia, and on psychopathological symptoms in general, and on social and neuropsychological functioning, and to study the influence of genetic polymorphisms in treatment response.

Raloxifene for Women With Alzheimer's Disease [Completed]
This is a multisite pilot randomized trial of raloxifene or placebo for the treatment of women with Alzheimer's disease.

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer [Active, not recruiting]
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Selective estrogen receptor modulators, such as raloxifene, may work together with bicalutamide to stop the growth of prostate cancer. PURPOSE: This clinical trial studies giving bicalutamide and raloxifene together in treating patients with metastatic or hormone-refractory prostate cancer.

Long Term Effects of Raloxifene Treatment on Bone Quality [Completed]
This is a cross-sectional study to determine, via iliac crest bone biopsies, the effect of long-term treatment with raloxifene on histomorphometry and bone quality in patients who participated in the Continuing Outcomes Relevant to Evista Study.

more trials >>

Reports of Suspected Evista (Raloxifene) Side Effects

Fall (43)HIP Fracture (26)Pain (22)Dizziness (22)Breast Cancer (21)Nausea (21)Drug Ineffective (20)Arthralgia (20)Vomiting (19)Femur Fracture (16)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 11 ratings/reviews, Evista has an overall score of 6.82. The effectiveness score is 6.55 and the side effect score is 7.45. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
 

Evista review by 64 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   high blood levels of thrombisin
Dosage & duration:   60mg taken 1 per day for the period of 3 years and still taking
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   normal thrombosin level within 6 weeks
Side effects:   none
Comments:   1 pill every morning

 

Evista review by 60 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   LOSS OF BONE DENSITY
Dosage & duration:   20MG taken everyday for the period of 5 YEARS
Other conditions:   NONE
Other drugs taken:   NONE
  
Reported Results
Benefits:   BONE DENSITY INCREASED. I HAD A BONE SCAN AND SHOWED ON THE BORDER LINE OF OSTEOPEROSIS, (?) WELL AFTER TAKING THIS DRUG, MY BONE MEASUREMENTS INCREASED. NO SIDE EFFECTS AND DEFIENTELY A GOOD MEDICATION FOR US BABY BOOMERS
Side effects:   NONE I DID NOT HAVE ANY SIDE EFFECTS, ONLY THAT MAYBE IT WILL HELP TO PREVENT BREAST CANCER, I HAVE A STRONG FAMILY HISTORY, MOTHER, GRANDMOTHER, AUNTS, COUSINS, WHO HAVE DIED OF BREAST CANCER. SO THIS MEDICATION IS A GOOD THING FOR ME.
Comments:   TOOK ONE TABLET A DAY, ALSO FOUND OUT IT HELPS TO PREVENT BREAST CANCER. I HAVE BEEN TAKING FOR OVER 5 YEARS NOW, I NEVER HAD A SIDE EFFECT, TAKE EVERYNIGHT WITH MY MEAL. NO ADVERSE EFFECTS. I WILL CONTINUE TO TAKE FOR THE REST OF MY LIFE.

 

Evista review by 51 year old female patient

  Rating
Overall rating:  
Effectiveness:   Ineffective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   osteopenia
Dosage & duration:   60 mg. taken once a day for the period of 2 weeks
Other conditions:   hypothyroidism
Other drugs taken:   levathyroxine, Lexapro, restasis
  
Reported Results
Benefits:   I didn't take the medicine long enough to get any benefits
Side effects:   I started having side effects within days of taking it but didn't realize it thinking that I was dealing with other health issues. I started out having a very bad sore throat, hoarse voice and cough. Went to a RediClini and got on antibiotic. Also went to see a Dr. 2 days later and was given a prednisone pack because I had chest congestion and by that time I had laryngitis plus shortness of breath. I dealt with these symptoms for 2 weeks. Cough and wheezing got better and then I realized the connection between getting all of these symptoms and the side effects. Checked online and sure enough, all of them were listed so I called the Dr. and stopped the medicine. Shortness of breath is better and my voice is getting somewhat better.
Comments:   None.

See all Evista reviews / ratings >>

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015